AU2010261541B2 - Stem accelerated isothermal nucleic acid amplification technology - Google Patents
Stem accelerated isothermal nucleic acid amplification technology Download PDFInfo
- Publication number
- AU2010261541B2 AU2010261541B2 AU2010261541A AU2010261541A AU2010261541B2 AU 2010261541 B2 AU2010261541 B2 AU 2010261541B2 AU 2010261541 A AU2010261541 A AU 2010261541A AU 2010261541 A AU2010261541 A AU 2010261541A AU 2010261541 B2 AU2010261541 B2 AU 2010261541B2
- Authority
- AU
- Australia
- Prior art keywords
- primer
- primers
- stem
- region
- amplification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003321 amplification Effects 0.000 title claims abstract description 170
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 170
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 33
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 31
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 31
- 238000005516 engineering process Methods 0.000 title description 10
- 238000000034 method Methods 0.000 claims abstract description 127
- 108091093088 Amplicon Proteins 0.000 claims description 157
- 239000002773 nucleotide Substances 0.000 claims description 72
- 125000003729 nucleotide group Chemical group 0.000 claims description 70
- 108091033319 polynucleotide Proteins 0.000 claims description 69
- 102000040430 polynucleotide Human genes 0.000 claims description 69
- 230000002441 reversible effect Effects 0.000 claims description 62
- 230000008569 process Effects 0.000 claims description 37
- 230000000295 complement effect Effects 0.000 claims description 34
- 239000000523 sample Substances 0.000 claims description 33
- 230000015572 biosynthetic process Effects 0.000 claims description 21
- 238000001514 detection method Methods 0.000 claims description 20
- 238000003786 synthesis reaction Methods 0.000 claims description 15
- 238000003556 assay Methods 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 238000011901 isothermal amplification Methods 0.000 claims description 7
- 238000005259 measurement Methods 0.000 claims description 7
- 244000005700 microbiome Species 0.000 claims description 7
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 claims description 5
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 claims description 5
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 claims description 5
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 claims description 5
- 230000002068 genetic effect Effects 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 4
- 235000011180 diphosphates Nutrition 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 3
- 101000743006 Lactococcus lactis subsp. cremoris UPF0177 protein in abiGi 5'region Proteins 0.000 claims description 3
- 108060001084 Luciferase Proteins 0.000 claims description 3
- 239000005089 Luciferase Substances 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 3
- 101150008979 mecA gene Proteins 0.000 claims description 3
- 229960003085 meticillin Drugs 0.000 claims description 3
- 206010067484 Adverse reaction Diseases 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 2
- 229930010555 Inosine Natural products 0.000 claims description 2
- 241000204031 Mycoplasma Species 0.000 claims description 2
- PJKKQFAEFWCNAQ-UHFFFAOYSA-N N(4)-methylcytosine Chemical compound CNC=1C=CNC(=O)N=1 PJKKQFAEFWCNAQ-UHFFFAOYSA-N 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 230000006838 adverse reaction Effects 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 238000002848 electrochemical method Methods 0.000 claims description 2
- 238000001962 electrophoresis Methods 0.000 claims description 2
- 238000003500 gene array Methods 0.000 claims description 2
- 244000037671 genetically modified crops Species 0.000 claims description 2
- 229960003786 inosine Drugs 0.000 claims description 2
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 235000003869 genetically modified organism Nutrition 0.000 claims 2
- 230000029918 bioluminescence Effects 0.000 claims 1
- 238000005415 bioluminescence Methods 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 13
- 238000007397 LAMP assay Methods 0.000 description 58
- 238000006073 displacement reaction Methods 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 24
- 230000007246 mechanism Effects 0.000 description 23
- 239000002157 polynucleotide Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 13
- 241000186779 Listeria monocytogenes Species 0.000 description 13
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 241000282326 Felis catus Species 0.000 description 11
- 230000037452 priming Effects 0.000 description 11
- 101000773513 Methanopyrus kandleri (strain AV19 / DSM 6324 / JCM 9639 / NBRC 100938) Uncharacterized protein MK0525 Proteins 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 241001122767 Theaceae Species 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 7
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- 230000003466 anti-cipated effect Effects 0.000 description 6
- 101710148896 Internalin A Proteins 0.000 description 5
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- IRLPACMLTUPBCL-KQYNXXCUSA-N 5'-adenylyl sulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](O)[C@H]1O IRLPACMLTUPBCL-KQYNXXCUSA-N 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 108090000331 Firefly luciferases Proteins 0.000 description 4
- 230000001133 acceleration Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 2
- 108700040632 Bacteria internalin Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 230000006819 RNA synthesis Effects 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108700031821 Bacteria invA Proteins 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 101150055297 SET1 gene Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000003263 homogeneous phase assay Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000012123 point-of-care testing Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0910302.9 | 2009-06-15 | ||
| GBGB0910302.9A GB0910302D0 (en) | 2009-06-15 | 2009-06-15 | Nucleic acid amplification |
| PCT/GB2010/001169 WO2010146349A1 (en) | 2009-06-15 | 2010-06-15 | Stem accelerated isothermal nucleic acid amplification technology |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2010261541A1 AU2010261541A1 (en) | 2012-02-02 |
| AU2010261541B2 true AU2010261541B2 (en) | 2016-03-10 |
Family
ID=40940851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010261541A Active AU2010261541B2 (en) | 2009-06-15 | 2010-06-15 | Stem accelerated isothermal nucleic acid amplification technology |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9410190B2 (enExample) |
| EP (1) | EP2443253B1 (enExample) |
| JP (2) | JP5907864B2 (enExample) |
| CN (1) | CN102652176B (enExample) |
| AU (1) | AU2010261541B2 (enExample) |
| CA (1) | CA2765406C (enExample) |
| ES (1) | ES2589079T3 (enExample) |
| GB (1) | GB0910302D0 (enExample) |
| WO (1) | WO2010146349A1 (enExample) |
| ZA (1) | ZA201109493B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5843614B2 (ja) | 2009-01-30 | 2016-01-13 | オックスフォード ナノポア テクノロジーズ リミテッド | 膜貫通配列決定における核酸構築物のためのアダプター |
| DK2633071T3 (en) | 2010-10-27 | 2017-01-30 | Harvard College | COMPOSITIONS OF "MAINTENANCE" PRIMER DUPLEXES AND METHODS OF USE |
| EP2714939B1 (en) | 2011-05-24 | 2015-04-15 | Elitech Holding B.V. | Detection of methicillin-resistant staphylococcus aureus |
| JP6298404B2 (ja) | 2011-07-25 | 2018-03-20 | オックスフォード ナノポール テクノロジーズ リミテッド | 膜貫通ポアを用いる二重鎖ポリヌクレオチド配列決定のためのヘアピンループ方法 |
| EP2875154B1 (en) | 2012-07-19 | 2017-08-23 | Oxford Nanopore Technologies Limited | SSB method for characterising a nucleic acid |
| GB201314695D0 (en) | 2013-08-16 | 2013-10-02 | Oxford Nanopore Tech Ltd | Method |
| AU2014224432B2 (en) | 2013-03-08 | 2019-10-24 | Oxford Nanopore Technologies Limited | Enzyme stalling method |
| US10450595B2 (en) | 2013-03-15 | 2019-10-22 | Theranos Ip Company, Llc | Nucleic acid amplification |
| WO2014145291A1 (en) | 2013-03-15 | 2014-09-18 | Theranos, Inc. | Nucleic acid amplification |
| SG11201507272RA (en) * | 2013-03-15 | 2015-10-29 | Theranos Inc | Nuclei acid amplification |
| WO2014151177A1 (en) | 2013-03-15 | 2014-09-25 | 3M Innovative Properties Company | Sample concentrator and method of use |
| CA2917206C (en) * | 2013-08-09 | 2021-09-21 | Genebio Systems, Inc. | Dna amplification via scissor-like structures (dasl) |
| SG11201601611WA (en) | 2013-09-06 | 2016-04-28 | Theranos Inc | Systems and methods for detecting infectious diseases |
| CN103497947B (zh) * | 2013-09-13 | 2015-08-12 | 浙江国际旅行卫生保健中心 | 一种体外新型快速环介导等温扩增方法、体外检测甲型h1n1流感病毒的试剂及方法 |
| CA2927315A1 (en) * | 2013-11-22 | 2015-05-28 | Theranos, Inc. | Nucleic acid amplification |
| EP3495506B1 (en) | 2013-12-11 | 2023-07-12 | AccuraGen Holdings Limited | Methods for detecting rare sequence variants |
| US11286519B2 (en) | 2013-12-11 | 2022-03-29 | Accuragen Holdings Limited | Methods and compositions for enrichment of amplification products |
| US11859246B2 (en) | 2013-12-11 | 2024-01-02 | Accuragen Holdings Limited | Methods and compositions for enrichment of amplification products |
| GB201403096D0 (en) | 2014-02-21 | 2014-04-09 | Oxford Nanopore Tech Ltd | Sample preparation method |
| US10716587B2 (en) | 2014-06-13 | 2020-07-21 | Surgis Medical Llc | Surgical device with light |
| CN106661600B (zh) | 2014-07-16 | 2021-04-06 | 唐恩生物科技股份有限公司 | 用于扩增核酸样品的等温方法 |
| US11559801B2 (en) | 2014-11-03 | 2023-01-24 | Tangen Biosciences, Inc. | Apparatus and method for cell, spore, or virus capture and disruption |
| ES2891085T3 (es) | 2015-01-30 | 2022-01-26 | Harvard College | Obtención de imágenes sin microscopio |
| GB2550712B (en) * | 2015-02-26 | 2021-01-13 | Hitachi High Tech Corp | Method for constructing hairpin-containing nucleic acid molecules for nanopore sequencing |
| US10260090B2 (en) | 2015-07-16 | 2019-04-16 | Arizona Board Of Regents On Behalf Of Arizona State University | Accelerated isothermal amplification of DNA |
| HK1259101A1 (zh) | 2015-10-09 | 2019-11-22 | Accuragen Holdings Limited | 用於富集扩增产物的方法及组合物 |
| US12163184B2 (en) | 2015-12-03 | 2024-12-10 | Accuragen Holdings Limited | Methods and compositions for forming ligation products |
| CN116949140A (zh) | 2016-02-17 | 2023-10-27 | 哈佛学院院长及董事 | 分子编程工具 |
| WO2017201102A1 (en) | 2016-05-16 | 2017-11-23 | Accuragen Holdings Limited | Method of improved sequencing by strand identification |
| GB201609220D0 (en) | 2016-05-25 | 2016-07-06 | Oxford Nanopore Tech Ltd | Method |
| CN107488656B (zh) * | 2016-06-13 | 2020-07-17 | 陆欣华 | 一种核酸等温自扩增方法 |
| WO2018035170A1 (en) | 2016-08-15 | 2018-02-22 | Accuragen Holdings Limited | Compositions and methods for detecting rare sequence variants |
| EP3568492B1 (en) * | 2017-01-10 | 2025-01-01 | President and Fellows of Harvard College | Multiplexed signal amplification |
| WO2019118912A1 (en) | 2017-12-14 | 2019-06-20 | Medicinal Genomics Corporation | Methods and kits for classifying cannabinoid production in cannabis plants |
| EP3743525A4 (en) | 2018-01-26 | 2021-09-29 | President and Fellows of Harvard College | PROXIMITY DETECTION METHODS AND COMPOSITIONS |
| GB201807793D0 (en) | 2018-05-14 | 2018-06-27 | Oxford Nanopore Tech Ltd | Method |
| CN112601823A (zh) | 2018-06-12 | 2021-04-02 | 安可济控股有限公司 | 用于形成连接产物的方法和组合物 |
| CN114045330B (zh) * | 2021-12-23 | 2024-02-09 | 川北医学院附属医院 | 一种基于滑动复制的核酸等温扩增方法 |
| CN118621045A (zh) * | 2024-08-14 | 2024-09-10 | 天健生物制药（天津）有限公司 | 基于lamp的鸟分枝杆菌检测的组合物和试剂盒 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002090538A1 (en) * | 2001-05-08 | 2002-11-14 | Eiken Kagaku Kabushiki Kaisha | Method of synthesizing nucleic acid |
| EP1988178A2 (en) * | 2007-04-26 | 2008-11-05 | Kabushiki Kaisha Toshiba | Nucleotide primer set and nucleotide probe for detecting genotype of serum amyloid A1(SAA1) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5866336A (en) * | 1996-07-16 | 1999-02-02 | Oncor, Inc. | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
| JP4918210B2 (ja) * | 2000-09-19 | 2012-04-18 | 栄研化学株式会社 | ポリヌクレオチドの合成方法 |
| GB0218215D0 (en) | 2002-08-06 | 2002-09-11 | Tepnel Medical Ltd | Amplification of nucleic acids |
| WO2007025281A2 (en) | 2005-08-24 | 2007-03-01 | Applera Corporation | A method to quantify sirnas, mirnas and polymorphic mirnas |
| JP4580875B2 (ja) * | 2006-01-20 | 2010-11-17 | 株式会社東芝 | 核酸検出法のためのプライマーの設計方法 |
| JP2008029333A (ja) | 2006-07-03 | 2008-02-14 | Fujifilm Corp | 新規遺伝子増幅法に用いられるプライマー |
| JP2010505438A (ja) | 2006-10-09 | 2010-02-25 | オキシテック・リミテッド | 核酸配列を増幅および検出する方法 |
| US8748100B2 (en) | 2007-08-30 | 2014-06-10 | The Chinese University Of Hong Kong | Methods and kits for selectively amplifying, detecting or quantifying target DNA with specific end sequences |
-
2009
- 2009-06-15 GB GBGB0910302.9A patent/GB0910302D0/en not_active Ceased
-
2010
- 2010-06-15 US US13/377,704 patent/US9410190B2/en active Active
- 2010-06-15 EP EP10725825.3A patent/EP2443253B1/en active Active
- 2010-06-15 ES ES10725825.3T patent/ES2589079T3/es active Active
- 2010-06-15 AU AU2010261541A patent/AU2010261541B2/en active Active
- 2010-06-15 CN CN201080035868.5A patent/CN102652176B/zh active Active
- 2010-06-15 CA CA2765406A patent/CA2765406C/en active Active
- 2010-06-15 WO PCT/GB2010/001169 patent/WO2010146349A1/en not_active Ceased
- 2010-06-15 JP JP2012515553A patent/JP5907864B2/ja active Active
-
2011
- 2011-12-22 ZA ZA2011/09493A patent/ZA201109493B/en unknown
-
2015
- 2015-10-09 JP JP2015201347A patent/JP6106732B2/ja not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002090538A1 (en) * | 2001-05-08 | 2002-11-14 | Eiken Kagaku Kabushiki Kaisha | Method of synthesizing nucleic acid |
| EP1988178A2 (en) * | 2007-04-26 | 2008-11-05 | Kabushiki Kaisha Toshiba | Nucleotide primer set and nucleotide probe for detecting genotype of serum amyloid A1(SAA1) |
Non-Patent Citations (1)
| Title |
|---|
| MISAWA, Y et al., Journal of Infection and Chemotherapy, 2007, vol. 13, pp134-140 * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB0910302D0 (en) | 2009-07-29 |
| JP2012529904A (ja) | 2012-11-29 |
| US9410190B2 (en) | 2016-08-09 |
| EP2443253A1 (en) | 2012-04-25 |
| ES2589079T3 (es) | 2016-11-10 |
| EP2443253B1 (en) | 2016-06-08 |
| ZA201109493B (en) | 2015-07-29 |
| JP2016041070A (ja) | 2016-03-31 |
| JP6106732B2 (ja) | 2017-04-05 |
| AU2010261541A1 (en) | 2012-02-02 |
| US20120157326A1 (en) | 2012-06-21 |
| CN102652176A (zh) | 2012-08-29 |
| CA2765406C (en) | 2019-02-26 |
| CN102652176B (zh) | 2016-09-28 |
| JP5907864B2 (ja) | 2016-04-26 |
| WO2010146349A1 (en) | 2010-12-23 |
| CA2765406A1 (en) | 2010-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010261541B2 (en) | Stem accelerated isothermal nucleic acid amplification technology | |
| AU2011319755B2 (en) | Compositions of toehold primer duplexes and methods of use | |
| US20220073967A1 (en) | Process for the enzymatic synthesis and amplification of nucleic acids | |
| US9200317B2 (en) | Nucleic acid amplification | |
| CN102753707A (zh) | 用随机引物和特异性引物的混合物等温扩增核酸 | |
| JP6638122B2 (ja) | 標的核酸の検出方法及びキット | |
| WO2017205510A1 (en) | Omega amplification | |
| US20180094309A1 (en) | Nucleic acid retro-activated primers | |
| JP2023518217A (ja) | 標的核酸を検出するためのループプライマー及びループ・デ・ループ方法 | |
| CN108350506A (zh) | 改进的短同聚重复的检测 | |
| US20220205031A1 (en) | Modified primers for nucleic acid amplification and detection | |
| EP3055430B1 (en) | Method for the detection of target nucleic acid sequences | |
| Bartholomew et al. | PCR, Real‐Time PCR, Digital PCR, and Isothermal Amplification | |
| JP2007319096A (ja) | エンドヌクレアーゼのニッキング活性を利用した核酸増幅法 | |
| CA3232224A1 (en) | Looped primer with various internal modifications and loop-de-loop method for target detection | |
| KR20240023114A (ko) | Lida(lesion induced dna amplification)에 의한 sars-cov-2 분석 | |
| Kundu et al. | Gene and Genome Editing | |
| HK1227444B (en) | Method for the detection of target nucleic acid sequences | |
| HK1227444A1 (en) | Method for the detection of target nucleic acid sequences |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ TISI, LAURENCE CARLO; GANDELMAN, OLGA; KIDDLE, GUY AND MCELGUNN, CATHAL JOSEPH |
|
| FGA | Letters patent sealed or granted (standard patent) |